Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has ...

As more cancers are being linked to the human papillomavirus (HPV), including cancers showing up in younger-than-average patients, a local doctor is promoting the use of the HPV vaccine, which is ...

Merck (MRK) anticipates full-year 2025 sales to be between $64.1B-$65.6B, including a negative impact of foreign exchange of approximately 2% ...

Rahway, N.J.-based Merck (MRK) had net income of $3.743 billion, or $1.48 a share, for the quarter, after a loss of $1.226 ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

US pharma giant Merck & Co opened Tuesday’s trading 10% lower after announcing its annual and fourth quarter financial ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.